Patents by Inventor Stephen Jay Kanes

Stephen Jay Kanes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12083131
    Abstract: Described herein are methods of treating tremor, e.g., essential tremor, depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: September 10, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Stephen Jay Kanes, Helen Colquhoun
  • Publication number: 20240245711
    Abstract: The present disclosure relates to methods of treating major depressive disorder (MDD) in a subject in need thereof by (i) performing an initial treatment course on the subject comprising administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, and (ii) performing 0, 1, or 2 subsequent treatment courses on the subject, wherein each subsequent treatment course comprises administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, in response to a recurrence of depression symptoms. The 0, 1, or 2 subsequent treatment courses can be performed over a period of 12 months from the beginning of the initial treatment course.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 25, 2024
    Inventors: Robert Alfonso Lasser, James Doherty, Jeffrey Martin Jonas, Stephen Jay Kanes, Handan Gunduz-Bruce, Joi Lisa Dunbar, Bambang Senoaji Adiwijaya
  • Publication number: 20240216395
    Abstract: The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 4, 2024
    Inventors: Robert Alfonso Lasser, James Doherty, Jeffrey Martin Jonas, Stephen Jay Kanes, Handan Gunduz-Bruce, Helen Anne Colquhoun, Ryan Arnold, Vijayveer Bonthapally, Joi Lisa Dunbar, Bambang Senoaji Adiwijaya
  • Publication number: 20240216396
    Abstract: The present disclosure relates to Compound (1), or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) in a human female subject during the subject's postnatal period, wherein the subject breastfeeds a child during the treatment period. The disclosure also relates to Compound (1), or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) in a human female subject, wherein the subject breastfeeds a child during the treatment period.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 4, 2024
    Inventors: Robert Alfonso Lasser, James Doherty, Jeffrey Martin Jonas, Stephen Jay Kanes, Handan Gunduz-Bruce, Amy E. Bullock, Jeffrey A. Wald
  • Patent number: 11884696
    Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: January 30, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Paul Steven Watson, Bret Berner, John Gregory Reid, Jian Wang, James J. Doherty, Stephen Jay Kanes
  • Publication number: 20230414636
    Abstract: Provided herein are methods for treating a symptom of a respiratory condition, in a subject, comprising administering to the subject an effective amount of a GABAA PAM.
    Type: Application
    Filed: March 24, 2021
    Publication date: December 28, 2023
    Inventor: Stephen Jay Kanes
  • Publication number: 20230399357
    Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.
    Type: Application
    Filed: August 24, 2023
    Publication date: December 14, 2023
    Inventors: Paul Steven Watson, Bret Berner, John Gregory Reid, Jian Wang, James J. Doherty, Stephen Jay Kanes
  • Publication number: 20230355639
    Abstract: Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
    Type: Application
    Filed: December 8, 2022
    Publication date: November 9, 2023
    Inventors: Stephen Jay Kanes, Helen Colquhoun
  • Publication number: 20230346801
    Abstract: Provided herein are methods for treating a symptom of a respiratory condition or a disease associated with a coronavirus, in a subject, comprising administering to the subject an effective amount of an agent selected from the group consisting of Compound (1) and Compound (2), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 24, 2021
    Publication date: November 2, 2023
    Inventor: Stephen Jay Kanes
  • Publication number: 20230310459
    Abstract: This disclosure relates to Compound 1, pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof, for the treatment of CNS related disorders, e.g., tremor, e.g., essential tremor; depression; and anxiety disorder, and methods for improving the effectiveness of the administration of Compound 1 for treating said CNS related disorders. The disclosure also relates to methods of increasing the bioavailability of a Compound 1 or pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof.
    Type: Application
    Filed: November 23, 2022
    Publication date: October 5, 2023
    Inventors: Ethan Hoffmann, George Nomikos, Handan Gunduz-Bruce, Stephen Jay Kanes
  • Publication number: 20230201224
    Abstract: Provided herein are methods for treating a sleep disorder, e.g., insomnia, in a subject, comprising administering to the subject an effective amount of a compound having the formula or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 1, 2023
    Publication date: June 29, 2023
    Inventors: James J. Doherty, Stephen Jay Kanes, Jeffrey M. Jonas, Inderjit Kaul
  • Publication number: 20230018765
    Abstract: Provided herein are methods for treating depression, such as major depressive disorder, in a subject in need thereof, comprising administering to the subject an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 5, 2020
    Publication date: January 19, 2023
    Inventors: Stephen Jay Kanes, James Doherty, Handan Gunduz-Bruce, Jeffrey Martin Jonas, Robert Alfonso Lasser
  • Patent number: 11554125
    Abstract: Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: January 17, 2023
    Assignee: Sage Therapeutics, Inc.
    Inventors: Stephen Jay Kanes, Helen Colquhoun
  • Publication number: 20220323462
    Abstract: Provided herein are methods for treating depression, such as postpartum depression or major depressive disorder, in a subject in need thereof, comprising administering to the subject an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof:
    Type: Application
    Filed: June 17, 2022
    Publication date: October 13, 2022
    Inventors: Stephen Jay Kanes, James J. Doherty, Handan Gunduz-Bruce, Jeffrey M. Jonas, Robert Alfonso Lasser
  • Publication number: 20220169674
    Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.
    Type: Application
    Filed: August 6, 2021
    Publication date: June 2, 2022
    Inventors: Paul Steven Watson, Bret Berner, John Gregory Reid, Jian Wang, James J. Doherty, Stephen Jay Kanes
  • Publication number: 20220110949
    Abstract: Provided herein are methods for treating a sleep disorder, e.g., insomnia, in a subject, comprising administering to the subject an effective amount of a compound having the formula (Compound 1) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 14, 2022
    Inventors: James J. Doherty, Stephen Jay Kanes, Jeffrey M. Jonas, Inderjit Kaul
  • Patent number: 11236121
    Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: February 1, 2022
    Assignee: Sage Therapeutics, Inc.
    Inventors: Paul Steven Watson, Bret Berner, John Gregory Reid, Jian Wang, James J. Doherty, Stephen Jay Kanes
  • Publication number: 20220023313
    Abstract: Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
    Type: Application
    Filed: March 8, 2021
    Publication date: January 27, 2022
    Inventors: Stephen Jay Kanes, Helen Colquhoun
  • Publication number: 20210338692
    Abstract: Provided herein are methods for treating depression, such as postpartum depression or major depressive disorder, in a subject in need thereof, comprising administering to the subject an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof: (Compound I).
    Type: Application
    Filed: June 12, 2019
    Publication date: November 4, 2021
    Inventors: Stephen Jay KANES, James J. DOHERTY, Handan GUNDUZ-BRUCE, Jeffrey M. JONAS, Robert Alfonso LASSER
  • Patent number: 10940156
    Abstract: Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: March 9, 2021
    Assignee: Sage Therapeutics, Inc.
    Inventors: Stephen Jay Kanes, Helen Colquhoun